Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis

Clin Gastroenterol Hepatol. 2004 Mar;2(3):183-97. doi: 10.1016/s1542-3565(04)00002-3.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Comorbidity
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / epidemiology*
  • Hepatitis C, Chronic / pathology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Liver Cirrhosis / epidemiology*
  • Liver Cirrhosis / pathology
  • Male
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins
  • Ribavirin / administration & dosage
  • Risk Assessment
  • Severity of Illness Index
  • Survival Rate
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Ribavirin